14-day Premium Trial Subscription Try For FreeTry Free
NASDAQ:DRNA
Delisted

Dicerna Pharmaceuticals Stock Price (Quote)

$38.22
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $38.22 $38.22 Friday, 27th May 2022 DRNA stock ended at $38.22. During the day the stock fluctuated 0% from a day low at $38.22 to a day high of $38.22.
90 days $38.22 $38.22
52 weeks $19.06 $40.14

Historical Dicerna Pharmaceuticals prices

Date Open High Low Close Volume
Jan 14, 2019 $10.96 $10.99 $10.37 $10.39 403 485
Jan 11, 2019 $11.30 $11.47 $11.02 $11.08 329 637
Jan 10, 2019 $11.38 $11.53 $10.92 $11.40 377 232
Jan 09, 2019 $11.52 $11.70 $11.34 $11.47 329 234
Jan 08, 2019 $11.72 $11.80 $11.15 $11.47 359 612
Jan 07, 2019 $11.91 $12.18 $11.35 $11.60 574 996
Jan 04, 2019 $11.20 $11.90 $10.99 $11.83 1 306 497
Jan 03, 2019 $11.73 $12.08 $10.86 $10.89 799 262
Jan 02, 2019 $10.55 $11.81 $9.86 $11.77 679 977
Dec 31, 2018 $10.72 $10.97 $10.49 $10.69 550 186
Dec 28, 2018 $10.12 $10.98 $9.95 $10.64 515 003
Dec 27, 2018 $10.32 $10.82 $9.71 $10.13 504 169
Dec 26, 2018 $9.89 $10.52 $9.74 $10.51 569 718
Dec 24, 2018 $9.52 $9.96 $9.31 $9.74 312 601
Dec 21, 2018 $10.57 $10.58 $9.51 $9.67 4 103 566
Dec 20, 2018 $10.92 $11.53 $10.11 $10.56 861 241
Dec 19, 2018 $11.54 $11.96 $10.60 $10.95 632 005
Dec 18, 2018 $11.90 $12.16 $10.77 $11.07 536 808
Dec 17, 2018 $12.08 $12.52 $11.67 $11.82 710 300
Dec 14, 2018 $12.19 $12.74 $12.05 $12.15 258 179
Dec 13, 2018 $13.45 $13.65 $12.31 $12.33 375 499
Dec 12, 2018 $13.04 $13.72 $12.97 $13.42 266 306
Dec 11, 2018 $12.87 $13.14 $12.51 $12.85 262 520
Dec 10, 2018 $12.90 $13.07 $12.52 $12.71 316 115
Dec 07, 2018 $13.89 $14.74 $12.72 $12.74 393 271
Click to get the best stock tips daily for free!

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherit... DRNA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT